SCHEMBL269115

SCHEMBL269115

CC(C)(C)NC(=O)c1cccnc1CCC(N)Cc1ccccc1F

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
DPP4 P27487 9/20 0.40
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
GLA P06280 1/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP9 Q86TI2 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
MAPK8 P45983 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269114 1.00 ANO1 (0.42) ANO1SMN1; SMN2NPC1LMNAMEN1
Hydrochloric Acid SCHEMBL269073 0.99 ANO1 (0.42) ANO1SMN1; SMN2NPC1LMNAMEN1
Hydrochloric Acid SCHEMBL269074 0.99 ANO1 (0.42) ANO1SMN1; SMN2NPC1LMNAMEN1
SCHEMBL269970 0.89 ALOX5AP (0.40) ANO1SMN1; SMN2DPP4ALOX5APFEN1
SCHEMBL269969 0.89 ALOX5AP (0.40) ANO1SMN1; SMN2DPP4ALOX5APFEN1
SCHEMBL270014 0.84 ANO1 (0.42) ANO1SMN1; SMN2NPC1LMNAMEN1
Hydrochloric Acid SCHEMBL269714 0.83 ANO1 (0.42) ANO1SMN1; SMN2NPC1LMNAMEN1
SCHEMBL268086 0.81 LMNA (0.43) ANO1SMN1; SMN2NPC1LMNAMEN1
Hydrochloric Acid SCHEMBL268138 0.78 ANO1 (0.40) ANO1SMN1; SMN2NPC1LMNAMEN1
SCHEMBL270127 0.75 LMNA (0.39) ANO1SMN1; SMN2NPC1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
EP-1912946-B1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS LILLY CO ELI (US) 2009-05-27 EP disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors DPP4, DPP3, DPP7 ANO1 3344/4885SMN1; SMN2 4330/4885NPC1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.